About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

Discovery of First-in-Class Calreticulin-targeted Degrader Antibody Conjugates Delivering a CDK9 Degrader Payload for the Treatment of CALR-mutated MPNs

Norman Fultang¹, Ashley Schwab¹, Sharayu Chandratre¹, Jake Karwoski¹, Grace Davis¹, Ian Johnson¹, Neha Bhagwat¹, Yue Zou¹, Arpita Mondal¹, Max Foroutan¹, Min Wang¹, Andrew Buesking¹, Chun Chen¹, Corey Basch¹, Ryan Holmes¹, Sang Hyun Lee¹, Diane Heiser¹, Andrew Combs¹, Peggy Scherle¹